Results 41 to 50 of about 12,151 (157)

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner   +52 more
wiley   +1 more source

Depresión y autoestima en pacientes con Espondiloartritis del Departamento de Reumatología del Hospital de Clínicas. San Lorenzo. Paraguay [PDF]

open access: yes, 2020
Introduction: Spondyloarthritis is an umbrella term for a group of chronic rheumatic diseases, genetically and clinically related, that lead to an important and often undervalued physical and psychological load.
Yinde, Yanira   +2 more
core   +1 more source

En Reumatología, ¿generamos los maestros que el siglo XXI necesita? [PDF]

open access: yes, 2021
¿Quiénes deberían ser maestros de la Reumatología Argentina? Uno pensaría los mejores. ¿Son los mejores? ¿Cuál debería ser el criterio de selección para tan honroso y destacado sitio?
Sergio Paira
core   +1 more source

Congreso PANLAR 2018

open access: yesRevista Argentina de Reumatología, 2018
Estimados Miembros de la Sociedad Argentina de Reumatología, Lectores de la Revista Argentina de Reumatología, amigos: con gran placer y alegría, escribo esta última invitación al ya inminente 20º Congreso PANLAR 2018, en Buenos Aires.
Enrique Soriano
doaj   +1 more source

Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry

open access: yesArthritis &Rheumatology, EarlyView.
Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti   +52 more
wiley   +1 more source

Por “Estudio multicéntrico no intervencional en pacientes con artritis reumatoidea tratados con tocilizumab”

open access: yesRevista Argentina de Reumatología, 2017
Estimado Editor: uno de los paradigmas en el tratamiento de la Artritis Reumatoidea (AR) ha sido la introducción de los agentes biológicos. 
Javier E. Rosa
doaj   +1 more source

Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis–associated pulmonary arterial hypertension: a EUSTAR analysis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Real‐world initial treatment strategies in SSc‐PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. Methods We analysed treatment‐naïve SSc‐PAH patients in EUSTAR (2000–2021) fulfilling the 2022 haemodynamic definition.
Hilde Jenssen Bjørkekjær   +30 more
wiley   +1 more source

Respuesta a “Reacción dermatológica fatal después de Infliximab”

open access: yesRevista Argentina de Reumatología, 2013
Sr. Editor: Hemos leído con especial interés el caso clínico de la Dra. Roqué y cols. recientemente publicado en su Revista y consideramos de importancia realizar algunos comentarios a las consideraciones y conclusiones de dicho reporte, ya que, si bien
Eduardo Mussano
doaj   +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2232-2245, November 2026.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis   +22 more
wiley   +1 more source

Comunicaciones orales

open access: yes, 2022
Presentadas durante el 55° Congreso Argentino de Reumatología del 12 al 15 de octubre de ...
Comité Científico del 55° Congreso Argentino de Reumatología
core   +1 more source

Home - About - Disclaimer - Privacy